Progesterone receptor isoform A may regulate the effects of neoadjuvant aglepristone in canine mammary carcinoma

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Progesterone receptor isoform A may regulate the effects of neoadjuvant aglepristone in canine mammary carcinoma. / Guil-Luna, Silvia; Stenvang, Jan; Brünner, Nils; De Andrés, Francisco Javier; Rollón, Eva; Domingo, Víctor; Sánchez-Céspedes, Raquel; Millán, Yolanda; Mulas, Juana Martín de las.

In: B M C Veterinary Research, Vol. 10, 296, 2014.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Guil-Luna, S, Stenvang, J, Brünner, N, De Andrés, FJ, Rollón, E, Domingo, V, Sánchez-Céspedes, R, Millán, Y & Mulas, JMDL 2014, 'Progesterone receptor isoform A may regulate the effects of neoadjuvant aglepristone in canine mammary carcinoma', B M C Veterinary Research, vol. 10, 296. https://doi.org/10.1186/s12917-014-0296-2

APA

Guil-Luna, S., Stenvang, J., Brünner, N., De Andrés, F. J., Rollón, E., Domingo, V., ... Mulas, J. M. D. L. (2014). Progesterone receptor isoform A may regulate the effects of neoadjuvant aglepristone in canine mammary carcinoma. B M C Veterinary Research, 10, [296]. https://doi.org/10.1186/s12917-014-0296-2

Vancouver

Guil-Luna S, Stenvang J, Brünner N, De Andrés FJ, Rollón E, Domingo V et al. Progesterone receptor isoform A may regulate the effects of neoadjuvant aglepristone in canine mammary carcinoma. B M C Veterinary Research. 2014;10. 296. https://doi.org/10.1186/s12917-014-0296-2

Author

Guil-Luna, Silvia ; Stenvang, Jan ; Brünner, Nils ; De Andrés, Francisco Javier ; Rollón, Eva ; Domingo, Víctor ; Sánchez-Céspedes, Raquel ; Millán, Yolanda ; Mulas, Juana Martín de las. / Progesterone receptor isoform A may regulate the effects of neoadjuvant aglepristone in canine mammary carcinoma. In: B M C Veterinary Research. 2014 ; Vol. 10.

Bibtex

@article{d746dae084cc4f43994e7ec03c0f66b5,
title = "Progesterone receptor isoform A may regulate the effects of neoadjuvant aglepristone in canine mammary carcinoma",
abstract = "BackgroundProgesterone receptors play a key role in the development of canine mammary tumours, and recent research has focussed on their possible value as therapeutic targets using antiprogestins. Cloning and sequencing of the progesterone receptor gene has shown that the receptor has two isoforms, A and B, transcribed from a single gene. Experimental studies in human breast cancer suggest that the differential expression of progesterone receptor isoforms has implications for hormone therapy responsiveness. This study examined the effects of the antiprogestin aglepristone on cell proliferation and mRNA expression of progesterone receptor isoforms A and B in mammary carcinomas in dogs treated with 20 mg/Kg of aglepristone (n¿=¿22) or vehicle (n¿=¿5) twice before surgery.ResultsFormalin-fixed, paraffin-embedded tissue samples taken before and after treatment were used to analyse total progesterone receptor and both isoforms by RT-qPCR and Ki67 antigen labelling. Both total progesterone receptor and isoform A mRNA expression levels decreased after treatment with aglepristone. Furthermore, a significant decrease in the proliferation index (percentage of Ki67-labelled cells) was observed in progesterone-receptor positive and isoform-A positive tumours in aglepristone-treated dogs.ConclusionsThese findings suggest that the antiproliferative effects of aglepristone in canine mammary carcinomas are mediated by progesterone receptor isoform A.",
keywords = "The Faculty of Health and Medical Sciences, Canine mammary carcinoma, Progesterone receptor, Isoforms, Aglepristone, Hormone treatment",
author = "Silvia Guil-Luna and Jan Stenvang and Nils Br{\"u}nner and {De Andr{\'e}s}, {Francisco Javier} and Eva Roll{\'o}n and V{\'i}ctor Domingo and Raquel S{\'a}nchez-C{\'e}spedes and Yolanda Mill{\'a}n and Mulas, {Juana Mart{\'i}n de las}",
year = "2014",
doi = "10.1186/s12917-014-0296-2",
language = "English",
volume = "10",
journal = "B M C Veterinary Research",
issn = "1746-6148",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Progesterone receptor isoform A may regulate the effects of neoadjuvant aglepristone in canine mammary carcinoma

AU - Guil-Luna, Silvia

AU - Stenvang, Jan

AU - Brünner, Nils

AU - De Andrés, Francisco Javier

AU - Rollón, Eva

AU - Domingo, Víctor

AU - Sánchez-Céspedes, Raquel

AU - Millán, Yolanda

AU - Mulas, Juana Martín de las

PY - 2014

Y1 - 2014

N2 - BackgroundProgesterone receptors play a key role in the development of canine mammary tumours, and recent research has focussed on their possible value as therapeutic targets using antiprogestins. Cloning and sequencing of the progesterone receptor gene has shown that the receptor has two isoforms, A and B, transcribed from a single gene. Experimental studies in human breast cancer suggest that the differential expression of progesterone receptor isoforms has implications for hormone therapy responsiveness. This study examined the effects of the antiprogestin aglepristone on cell proliferation and mRNA expression of progesterone receptor isoforms A and B in mammary carcinomas in dogs treated with 20 mg/Kg of aglepristone (n¿=¿22) or vehicle (n¿=¿5) twice before surgery.ResultsFormalin-fixed, paraffin-embedded tissue samples taken before and after treatment were used to analyse total progesterone receptor and both isoforms by RT-qPCR and Ki67 antigen labelling. Both total progesterone receptor and isoform A mRNA expression levels decreased after treatment with aglepristone. Furthermore, a significant decrease in the proliferation index (percentage of Ki67-labelled cells) was observed in progesterone-receptor positive and isoform-A positive tumours in aglepristone-treated dogs.ConclusionsThese findings suggest that the antiproliferative effects of aglepristone in canine mammary carcinomas are mediated by progesterone receptor isoform A.

AB - BackgroundProgesterone receptors play a key role in the development of canine mammary tumours, and recent research has focussed on their possible value as therapeutic targets using antiprogestins. Cloning and sequencing of the progesterone receptor gene has shown that the receptor has two isoforms, A and B, transcribed from a single gene. Experimental studies in human breast cancer suggest that the differential expression of progesterone receptor isoforms has implications for hormone therapy responsiveness. This study examined the effects of the antiprogestin aglepristone on cell proliferation and mRNA expression of progesterone receptor isoforms A and B in mammary carcinomas in dogs treated with 20 mg/Kg of aglepristone (n¿=¿22) or vehicle (n¿=¿5) twice before surgery.ResultsFormalin-fixed, paraffin-embedded tissue samples taken before and after treatment were used to analyse total progesterone receptor and both isoforms by RT-qPCR and Ki67 antigen labelling. Both total progesterone receptor and isoform A mRNA expression levels decreased after treatment with aglepristone. Furthermore, a significant decrease in the proliferation index (percentage of Ki67-labelled cells) was observed in progesterone-receptor positive and isoform-A positive tumours in aglepristone-treated dogs.ConclusionsThese findings suggest that the antiproliferative effects of aglepristone in canine mammary carcinomas are mediated by progesterone receptor isoform A.

KW - The Faculty of Health and Medical Sciences

KW - Canine mammary carcinoma

KW - Progesterone receptor

KW - Isoforms

KW - Aglepristone

KW - Hormone treatment

U2 - 10.1186/s12917-014-0296-2

DO - 10.1186/s12917-014-0296-2

M3 - Journal article

VL - 10

JO - B M C Veterinary Research

JF - B M C Veterinary Research

SN - 1746-6148

M1 - 296

ER -

ID: 135227339